Demographics and lifestyle characteristics of cases and controls of the Prostate Cancer Prevention Trial participants in the treatment arm (n = 1273).

<p>Demographics and lifestyle characteristics of cases and controls of the Prostate Cancer Prevention Trial participants in the treatment arm (n = 1273).</p

Associations of finasteride concentrations with prostate cancer risk in PCPT, overall and stratified by cancer grade.

<p>Associations of finasteride concentrations with prostate cancer risk in PCPT, overall and stratified by cancer grade.</p

Mean finasteride levels (ng/mL) stratified by categories of demographic measures among treatment-compliant men in the Prostate Cancer Prevention Trial finasteride arm.

<p>Mean finasteride levels (ng/mL) stratified by categories of demographic measures among treatment-compliant men in the Prostate Cancer Prevention Trial finasteride arm.</p

Association between finasteride concentrations and genes in metabolism and target pathways among white men. ^#

<p>Association between finasteride concentrations and genes in metabolism and target pathways among white men. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0126672#t004fn001" target="_blank">^#</a></p

Vitamin-D related single nucleotide polymorphisms (SNPs) with p-values <0.05 and risk of pancreatic cancer from PanScan I-III (3,583 cases and 7,053 controls).

<p>^a After bonferroni correction (0.05/213) p-values < 0.0002 were considered significant</p><p>^b Odds ratios (ORs) were adjusted for age (≤50, 51–60, 61–70, 71–80, ≥81 years), sex, study, and population stratification by 5 eigenvectors for ethnic ancestry.</p><p>^c Odds ratios (ORs) are for the number of copies of the minor allele.</p><p>^d Phase refers to participation in PanScan I, II or III. For rs4668123 data was available only from PanScan phases II and III.</p><p>Vitamin-D related single nucleotide polymorphisms (SNPs) with p-values <0.05 and risk of pancreatic cancer from PanScan I-III (3,583 cases and 7,053 controls).</p

Pathway analysis for risk of pancreatic cancer and gene sets in the vitamin D pathway (3,583 cases and 7,053 controls)

<p>^aP-values account for number of SNPs within genes or within the overall pathway, but not for the total number of genes; Models were adjusted for age (≤50, 51–60, 61–70, 71–80, ≥81 years), sex, study and population stratification by 5 eigenvectors for ethnic ancestry.</p><p>Pathway analysis for risk of pancreatic cancer and gene sets in the vitamin D pathway (3,583 cases and 7,053 controls)</p

Relative geometric mean concentrations* of male sex hormones by height categories.

<p>*relative to 175.0–179.9 cm, adjusted for study, age and BMI. Abbreviations: A-diol-G = Androstanediol glucuronide; CI = confidence interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.</p

Partial correlation coefficients in control subjects between log-transformed concentrations of sex hormones and SHBG.

<p>Partial correlation coefficients in control subjects between log-transformed concentrations of sex hormones and SHBG.</p

Assay methods and geometric mean sex hormone and SHBG concentrations.

<p>Assay methods and geometric mean sex hormone and SHBG concentrations.</p

Relative geometric mean concentrations* of male sex hormones by time of blood collection.

<p>*relative to before 09:00, adjusted for study, age and BMI. #significant interaction with study P<0.01. Abbreviations: A-diol-G = Androstanediol glucuronide; CI = confidence interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.</p